PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.
Alanna M Chamberlain, Yan Gong, Kathryn McAuliffe Shaw...
https://pubmed.ncbi.nlm.nih.gov/31020929/Actively Recruiting
Led by Duke University · Updated on 2026-10-29
6000
Participants Needed
149
Research Sites
8 weeks
Total Duration
Researchers are evaluating the effectiveness of inclisiran, a subcutaneous injection given twice yearly, in preventing major cardiovascular and limb events in patients who have undergone percutaneous coronary or peripheral endovascular revascularization. This phase 4, randomized, double-blind, placebo-controlled study involves about 6,000 participants with symptomatic atherosclerotic cardiovascular disease, including coronary artery disease and peripheral artery disease. The goal is to understand how inclisiran can be used alongside usual care in real-world clinical settings. Participants will receive either inclisiran sodium 300 mg or a matching placebo by subcutaneous injection on Day 1, Month 3 Day 90, and every 6 months thereafter. Treatment starts within 14 days after a successful coronary or peripheral endovascular intervention. Both groups will continue their usual care as directed by their physicians. The study is event-driven and will continue until about 2,380 major events have occurred, with a treatment duration of up to approximately 45 months and an average follow-up of about 36 months. Throughout the study, participants will be regularly monitored for major adverse cardiovascular events and limb events, as well as other outcomes such as cardiovascular death, all-cause death, and venous thromboembolic events. Follow-up will last around 4 years. Assessments include clinical evaluations and ongoing observation to measure the impact of inclisiran compared to placebo while ensuring participant safety and adherence to the study protocol.
CONDITIONS
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
R
Robin Barron-Nelson, RN, MSN
J
Jen Holt
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Duke University
Lead Sponsor
Novartis Pharmaceuticals
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Inclisiran sodium injection | Placebo injection | Current guideline-supported therapy |
|---|---|---|---|
| What it is | Inclisiran sodium is a small interfering RNA drug injected subcutaneously every 6 months that lowers LDL cholesterol by inhibiting PCSK9 production. | Placebo is a saline injection given on the same schedule as inclisiran, without active PCSK9 inhibition or cholesterol-lowering effect. | Current guideline-supported therapy includes high-intensity statins, ezetimibe, and PCSK9 inhibitors as needed to achieve LDL targets, as recommended by ACC/AHA guidelines after coronary or peripheral intervention. |
| Role in trial | Investigational arm: randomised patients receive inclisiran to test prevention of cardiovascular and limb events. | Control arm: randomised patients receive placebo injections as trial comparator. | External context: standard-care therapy is not a trial arm but represents routine US practice for eligible patients. |
| Primary use | Intended to reduce major adverse cardiovascular and limb events by lowering LDL cholesterol after PCI or PVI. | Serves as an inactive comparator, with no expected impact on cardiovascular or limb events. | Used to lower LDL cholesterol aggressively and reduce risk of cardiovascular and limb events post-intervention, per current US guidelines. |
| How it is given or performed | Administered as a 300 mg subcutaneous injection at Day 0, Day 90, and every 6 months. | Administered as a saline subcutaneous injection matching the inclisiran schedule. | Statins, ezetimibe, or PCSK9 inhibitors are taken orally or by subcutaneous injection, with statins and ezetimibe given daily and PCSK9 inhibitors every 2–4 weeks. |
| Evidence status | Multiple studies show substantial LDL reduction with inclisiran, but definitive long-term cardiovascular event data are awaited in this high-risk population. | No active LDL-lowering effect; serves as reference for investigational efficacy. | Large-scale evidence and guidelines confirm high-intensity statins with adjunct therapies effectively reduce major cardiovascular events and limb events in post-PCI/PVI patients. |
| Important limitations | Long-term cardiovascular event reduction in this population remains unproven; safety in patients with advanced comorbidities requires further monitoring. | Placebo does not lower cholesterol or prevent vascular events; outcomes reflect natural history under trial protocol. | Some patients do not achieve target LDL levels despite intensive therapy and may be ineligible for PCSK9 inhibitors due to cost or access barriers. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to approximately 45 months
Participants receive inclisiran or placebo injections starting within 14 days after their successful coronary or peripheral endovascular intervention. Injections are given on Day 1, Month 3, and every 6 months thereafter, alongside usual medical care.
Injections on Day 1, Month 3, and every 6 months thereafter with regular follow-up visits
Duration - Up to approximately 4 years
Participants are monitored for major cardiovascular and limb events, as well as other health outcomes, for up to about 4 years from randomization. Ongoing assessments help evaluate the study outcomes and participant safety.
Regular monitoring visits throughout the study period
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Alanna M Chamberlain, Yan Gong, Kathryn McAuliffe Shaw...
https://pubmed.ncbi.nlm.nih.gov/31020929/Ann Marie Navar, Nishant P Shah, Peter Shrader...
https://pubmed.ncbi.nlm.nih.gov/38972336/Duke University
Lead Sponsor
Novartis Pharmaceuticals
Collaborating Sponsor